Literature DB >> 22074356

Duane retraction syndrome: series of 441 cases.

Ramesh Kekunnaya1, Amit Gupta, Virender Sachdeva, Sannapaneni Krishnaiah, B Venkateshwar Rao, Urvish Vashist, Debajit Ray.   

Abstract

PURPOSE: To determine the demographic and clinical profile of various subtypes of Duane retraction syndrome (DRS).
METHODS: Retrospective case series of 441 patients.
RESULTS: Of the total 441 patients, 389 (88.2%) and 52 (11.8%) patients had unilateral and bilateral involvement, respectively. In both unilateral and bilateral cases, type I was the most common subtype, followed by types III and II. Mean age of presentation of type I DRS was significantly less (13.3 years) compared with types II (23 years) and III (21.9 years) (P < .05). Unilateral disease was significantly more common in females (57. 6%, P = .006), whereas there was no gender predilection in bilateral cases (P = .77). Type 1 DRS was significantly more common among females (57.96%, P = .003) compared with males, whereas there was no such gender predilection in types II and III. The left eye was more commonly involved in patients with types I and III (P < .05), whereas in type II there was no such predilection for any eye involvement. Esotropia was more common in patients with bilateral disease (53.8%) and exotropia was predominant ocular deviation in patients with types II and III (70% and 66.67%, P = .03). There was no difference in the type of deviation in patients with type I (P > .05). Upshoots and downshoots were more common in unilateral disease and types I and III compared with type II.
CONCLUSION: Unilateral and bilateral DRS show considerable differences in gender distribution, associated ocular deviation, overshoots, and ocular and systemic associations. Copyright 2012, SLACK Incorporated.

Entities:  

Mesh:

Year:  2011        PMID: 22074356     DOI: 10.3928/01913913-20111101-01

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  9 in total

1.  Lateral rectus muscle recession for intermittent exotropia with anomalous head position in type 1 Duane's retraction syndrome.

Authors:  Ju-Yeun Lee; Kyung-Ah Park; Sei Yeul Oh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-30       Impact factor: 3.117

Review 2.  Isolated Abducens Nerve Palsy: Update on Evaluation and Diagnosis.

Authors:  Christopher Elder; Clotilde Hainline; Steven L Galetta; Laura J Balcer; Janet C Rucker
Journal:  Curr Neurol Neurosci Rep       Date:  2016-08       Impact factor: 5.081

3.  Botulinum toxin injection in the patients with Duane syndrome type 1.

Authors:  Ahmad Ameri; Farzad Farzbod; Fatemeh Bazvand; Arash Mirmohammadsadeghi; Mohammadreza Akbari; Faramarz Anvari; Simindokht Hosseini
Journal:  J Curr Ophthalmol       Date:  2016-11-12

Review 4.  Duane retraction syndrome: causes, effects and management strategies.

Authors:  Ramesh Kekunnaya; Mithila Negalur
Journal:  Clin Ophthalmol       Date:  2017-10-30

5.  Duane retraction syndrome in a patient with abnormal head position.

Authors:  Şule Gökçe; Zeynep Büşra Albayram; Gülizar Turan; Elif Demirkılınç Biler; Sema Aydoğdu
Journal:  Turk Pediatri Ars       Date:  2019-09-25

6.  The clinical characteristics of Duane retraction syndrome in Al-Medina region.

Authors:  Ahdab Q Alreheli; Mohammad M Aloufi; Waseem Aalam; Essam S Kordi; Hussain F Al-Habboubi
Journal:  Saudi J Ophthalmol       Date:  2019-08-08

7.  Clinical profile and magnetic resonance imaging characteristics of Duane retraction syndrome.

Authors:  Unnikrishnan Suma; Mohammed Ferzana; Valiyaveetil Babitha; Poothatta Jyothi
Journal:  Oman J Ophthalmol       Date:  2022-06-29

8.  Clinical Features of Duane Retraction Syndrome: A New Classification.

Authors:  Yun Jeong Lee; Haeng Jin Lee; Seong Joon Kim
Journal:  Korean J Ophthalmol       Date:  2020-04

9.  Ocular structural changes in patients with Duane retraction syndrome: Does a correlation exist?

Authors:  Ramesh Kekunnaya; Bhagya L Marella; Hari K Peguda; Virender Sachdeva
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.